

October 24, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/Madam,

Sub: Intimation of Board Meeting.

This is to inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Wednesday, November 5, 2025**, to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025.

Further to our letter dated September 24, 2025 whereby we informed the closure of Trading Window of the Company from July 1, 2025 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025, we inform you that the Trading Window will remain closed up to November 7, 2025 and shall be re-opened on November 8, 2025.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary